Success Metrics

Clinical Success Rate

100.0%

Based on 5 completed trials

Completion Rate

100%(5/5)

Active Trials

0(0%)

Results Posted

20%(1 trials)

Phase Distribution

Ph phase_1

25%

Ph not_applicable

25%

Ph phase_3

50%

Ph phase_4

25%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution5 total trials

Phase 1Safety & dosage

1(20.0%)

Phase 3Large-scale testing

2(40.0%)

Phase 4Post-market surveillance

1(20.0%)

N/ANon-phased studies

1(20.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

5 of 5 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Completed(5)

Detailed Status

Completed5

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

100.0%

Most Advanced

Phase 4

Trials by Phase

Phase 11 (20.0%)

Phase 32 (40.0%)

Phase 41 (20.0%)

N/A1 (20.0%)

Trials by Status

completed5100%

Recent Activity

0 active trials

Showing 4 of 4

completedphase_4

A Study to Assess the Reduction of Daily Maintenance ICS/LABA Treatment Towards Anti-Inflammatory Reliever Treatment in Patients With Severe Eosinophilic Asthma Treated With Benralizumab

NCT04159519

completedphase_1

Clinical Trials (4)

Showing 4 of 4 trials

NCT04159519Phase 4

A Study to Assess the Reduction of Daily Maintenance ICS/LABA Treatment Towards Anti-Inflammatory Reliever Treatment in Patients With Severe Eosinophilic Asthma Treated With Benralizumab

Completed

NCT04929626Phase 1

Different Doses of Nebulized Magnesium Sulphate in Status Asthmaticus

Completed

NCT03468790Phase 3

Anti-IgE Monoclonal Antibody Treatment in Patients With Allergic Asthma.

Completed

NCT00876135Not Applicable

Role of Airway Hyperresponsiveness on Performance in Elite Swimmers.

Completed

All 4 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 4